Novo Nordisk ONWARDS 3 and 4 Trials Achieve Primary Endpoints

(PLX AI) – Novo Nordisk achieves primary objectives of ONWARDS 3 and 4 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin degludec in ONWARDS 3.Novo Nordisk trial achieved its primary endpoint of …